Abstract
Lenvatinib is an inhibitor of tyrosine kinases, such as vascular endothelial growth factor receptor and fibroblast growth factor receptor, and was first approved for use in thyroid cancer in 2015 in Japan. Additional approval was given in March 2018 for its use as a first-line treatment for advanced or unresectable hepatocellular carcinoma. Herein, we report a case of pneumothorax during lenvatinib treatment for multiple lung metastases of hepatocellular carcinoma in a 71-year-old man. Although the development of pneumothorax during treatment with anticancer agents for lung metastases is well-known, this is the first report of pneumothorax induced by lenvatinib during treatment for lung metastases of hepatocellular carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yamada N, Abe N, Usui K, et al. Clinical analysis of 12 cases of pneumothorax during intensive chemotherapy for malignant neoplasms [in Japanese]. Gan To Kagaku Ryoho. 2010;37:1519–23.
Kazzaz FI, Cabanillas ME, Bashoura L, et al. Bilateral spontaneous pneumothoraces in anaplastic thyroid cancer. Respir Med Case Rep. 2019;26:197–9.
Yamazaki H, Iwasaki H, Yamashita T, et al. A case of pneumothorax after treatment with lenvatinib for anaplastic thyroid cancer with lung metastasis. Case Rep Endocrinol. 2018:7875929. https://doi.org/10.1155/2018/7875929
Berdelou A, Borget I, Godbert Y, et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid. 2018;28:72–8.
Iida T, Yabana T, Nakagaki S, et al. A rupture of a lung metastatic lesion of colon cancer, leading to pneumothorax caused by bevacizumab. Intern Med. 2016;55:3125–9.
Tanaka S, Aoki M, Ishikawa H, et al. A case of refractory pneumothorax during bevacizumab-containing chemotherapy for multiple lung metastases from colon cancer [in Japanese]. Jpn J Chest Surg. 2013;27:611–5.
Alrifai T, Saba R, Rifai D, et al. Pneumothorax following combination chemotherapy with bevacizumab: a case report and review of the literature. Mol Clin Oncol. 2019;11:173–6.
Yang SH, Lin JK, Chen WS, et al. Pneumothorax after bevacizumab-containing chemotherapy: a case report. Jpn J Clin Oncol. 2011;41:269–71.
Tamura T, Tamura S, Nasu H, et al. A case of intractable pneumothorax in a patient with pulmonary adenocarcinoma during bevacizumab-containing chemotherapy [in Japanese]. Nihon Kokyuki Gakkai Zasshi. 2011;49:702–6.
Kono T, Miyata R, Takagi J, et al. Development of pyopneumothorax during bevacizumab-containing chemotherapy in a patient with lung adenocarcinoma [in Japanese]. Haigan Lung cancer. 2013;53:336–40.
Kodama A, Doi M, Hamai K, et al. A case of pulmonary sarcomatoid carcinoma with pneumothorax after bevacizumab-combined chemotherapy [in Japanese]. Haigan Lung cancer. 2012;52:1041–6.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Informed consent
Informed consent was obtained from all patients for being included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kawanishi, Y., Kuwahara, M., Utsunomiya, M. et al. Pneumothorax during lenvatinib treatment for hepatocellular carcinoma with lung metastasis. Clin J Gastroenterol 14, 288–292 (2021). https://doi.org/10.1007/s12328-020-01273-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-020-01273-7